Cargando…

Presence of CD133‐positive circulating tumor cells predicts worse progression‐free survival in patients with metastatic castration‐sensitive prostate cancer

OBJECTIVE: To investigate the clinical significance of the expression of the stemness marker CD133 in circulating tumor cells of newly diagnosed metastatic castration‐sensitive prostate cancer patients. METHODS: For this study, 104 metastatic castration‐sensitive prostate cancer patients treated at...

Descripción completa

Detalles Bibliográficos
Autores principales:	Yang, Yunjie, Liu, Zheng, Wang, Qifeng, Chang, Kun, Zhang, Junyu, Ye, Dingwei, Kong, Yunyi, Dai, Bo
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley and Sons Inc. 2022
Materias:	Original Articles: Clinical Investigation
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9305754/ https://www.ncbi.nlm.nih.gov/pubmed/35102615 http://dx.doi.org/10.1111/iju.14801

Ejemplares similares

Constitutively Active AR-V7 Plays an Essential Role in the Development and Progression of Castration-Resistant Prostate Cancer
por: Qu, Yuanyuan, et al.
Publicado: (2015)

The prevalence and prognosis of next‐generation therapeutic targets in metastatic castration‐resistant prostate cancer
por: Pan, Jian, et al.
Publicado: (2022)

Biomarker-Directed Therapy in Black and White Men With Metastatic Castration-Resistant Prostate Cancer
por: Hwang, Clara, et al.
Publicado: (2023)

Assessment of a Clinical Trial–Derived Survival Model in Patients With Metastatic Castration-Resistant Prostate Cancer
por: Coquet, Jean, et al.
Publicado: (2021)

Prostate-Specific Membrane Antigen Expression on PET/CT in Patients with Metastatic Castration-Resistant Prostate Cancer: A Retrospective Observational Study
por: Calderoni, Letizia, et al.
Publicado: (2023)

Combination of circulating tumor cell enumeration and tumor marker detection in predicting prognosis and treatment effect in metastatic castration-resistant prostate cancer
por: Chang, Kun, et al.
Publicado: (2015)

(177)Lu-Prostate-Specific Membrane Antigen Therapy in Patients with Metastatic Castration-Resistant Prostate Cancer and Prior (223)Ra (RALU Study)
por: Rahbar, Kambiz, et al.
Publicado: (2023)

Relationship between Circulating Lipids and Cytokines in Metastatic Castration-Resistant Prostate Cancer
por: Lin, Hui-Ming, et al.
Publicado: (2021)

Association of Chemotherapy, Enzalutamide, Abiraterone, and Radium 223 With Cognitive Function in Older Men With Metastatic Castration-Resistant Prostate Cancer
por: Alibhai, Shabbir M. H., et al.
Publicado: (2021)

Comparative Effectiveness of Immune Checkpoint Inhibitors vs Chemotherapy by Tumor Mutational Burden in Metastatic Castration-Resistant Prostate Cancer
por: Graf, Ryon P., et al.
Publicado: (2022)

Outcomes Among African American and Non-Hispanic White Men With Metastatic Castration-Resistant Prostate Cancer With First-Line Abiraterone
por: Marar, Mallika, et al.
Publicado: (2022)

Pain Outcomes in Patients with Metastatic Castration-Resistant Prostate Cancer Treated with (223)Ra: PARABO, a Prospective, Noninterventional Study
por: Palmedo, Holger, et al.
Publicado: (2023)

Olaparib outcomes in metastatic castration-resistant prostate cancer: First real-world experience in safety and efficacy from the Chinese mainland
por: Pan, Jian, et al.
Publicado: (2022)

Race and Treatment Outcomes in Patients With Metastatic Castration-Sensitive Prostate Cancer: A Secondary Analysis of the SWOG 1216 Phase 3 Trial
por: Sayegh, Nicolas, et al.
Publicado: (2023)

Characterizing Circulating Tumor Cells and Tumor-Derived Extracellular Vesicles in Metastatic Castration-Naive and Castration-Resistant Prostate Cancer Patients
por: Isebia, Khrystany T., et al.
Publicado: (2022)

Low TIM3 expression indicates poor prognosis of metastatic prostate cancer and acts as an independent predictor of castration resistant status
por: Wu, Junlong, et al.
Publicado: (2017)

Blood Circulating CD133+ Extracellular Vesicles Predict Clinical Outcomes in Patients with Metastatic Colorectal Cancer
por: Brocco, Davide, et al.
Publicado: (2022)

Isolation and genomic analysis of circulating tumor cells from castration resistant metastatic prostate cancer
por: Magbanua, Mark Jesus M, et al.
Publicado: (2012)

Circulating Cell-Free DNA as Biomarker of Taxane Resistance in Metastatic Castration-Resistant Prostate Cancer
por: Francini, Edoardo, et al.
Publicado: (2021)

Assessment of the Safety of Glucocorticoid Regimens in Combination With Abiraterone Acetate for Metastatic Castration-Resistant Prostate Cancer: A Randomized, Open-label Phase 2 Study
por: Attard, Gerhardt, et al.
Publicado: (2019)

Utilization and Outcomes of Surgical Castration in Comparison to Medical Castration in Metastatic Prostate Cancer
por: Garje, Rohan, et al.
Publicado: (2019)

Survival Outcomes by Race and Ethnicity in Veterans With Nonmetastatic Castration-Resistant Prostate Cancer
por: Rasmussen, Kelli M., et al.
Publicado: (2023)

Prostate Cancer Stem Cells: The Role of CD133
por: Yang, Jianhui, et al.
Publicado: (2022)

Chinese Expert Consensus on the Diagnosis and Treatment of Castration-Resistant Prostate Cancer (2019 Update)
por: Zhu, Yao, et al.
Publicado: (2020)

Circulating AR copy number and outcome to enzalutamide in docetaxel-treated metastatic castration-resistant prostate cancer
por: Salvi, Samanta, et al.
Publicado: (2016)

Circulating Tumor Cell Enumeration and Characterization in Metastatic Castration-Resistant Prostate Cancer Patients Treated with Cabazitaxel
por: de Kruijff, Ingeborg E., et al.
Publicado: (2019)

Large Extracellular Vesicle Characterization and Association with Circulating Tumor Cells in Metastatic Castrate Resistant Prostate Cancer
por: Gerdtsson, Anna S., et al.
Publicado: (2021)

Association of Circulating Tumor Cells with Inflammatory and Biomarkers in the Blood of Patients with Metastatic Castration-Resistant Prostate Cancer
por: Theil, Gerit, et al.
Publicado: (2021)

Analysis of Circulating Immune Biomarkers by Race in Men With Metastatic Castration-Resistant Prostate Cancer Treated With Sipuleucel-T
por: Hawley, Jessica E, et al.
Publicado: (2021)

Transcriptome Profiling of Circulating Tumor Cells to Predict Clinical Outcomes in Metastatic Castration-Resistant Prostate Cancer
por: Groen, Levi, et al.
Publicado: (2023)

CD133 Promotes Adhesion to the Ovarian Cancer Metastatic Niche
por: Roy, Lynn, et al.
Publicado: (2018)

Impact of Time to Castration Resistance on Cytoreductive Radiotherapy in Metastatic Castration-Resistant Prostate Cancer
por: Mai, Lixin, et al.
Publicado: (2020)

Novel Framework for Treatment Response Evaluation Using PSMA PET/CT in Patients with Metastatic Castration-Resistant Prostate Cancer (RECIP 1.0): An International Multicenter Study
por: Gafita, Andrei, et al.
Publicado: (2022)

Circulating Tumour Cells Indicate the Presence of Residual Disease Post-Castration in Prostate Cancer Patient-Derived Xenograft Models
por: Hassan, Sara, et al.
Publicado: (2022)

A multicenter observational study of the real‐world use of docetaxel for metastatic castration‐resistant prostate cancer in China
por: He, Dalin, et al.
Publicado: (2019)

Preliminary results of targeted prostate‐specific membrane antigen imaging in evaluating the efficacy of a novel hormone agent in metastatic castration‐resistant prostate cancer
por: Liu, Chang, et al.
Publicado: (2020)

Radium-223 in metastatic castration resistant prostate cancer
por: Vuong, Winston, et al.
Publicado: (2014)

Treatment sequencing in metastatic castrate-resistant prostate cancer
por: Sartor, Oliver, et al.
Publicado: (2014)

Abiraterone in the treatment of metastatic castration-resistant prostate cancer
por: Mostaghel, Elahe A
Publicado: (2014)

Enzalutamide for patients with metastatic castration-resistant prostate cancer
por: Ramadan, Wijdan H, et al.
Publicado: (2015)

Cannot write session to /tmp/vufind_sessions/sess_o80uuo3ajvkhrd6pkdmrvt2esb